PIK3CA mutation and colorectal cancer precision medicine

Tsuyoshi Hamada; Jonathan A Nowak; Shuji Ogino

doi:10.18632/oncotarget.15724

PIK3CA mutation and colorectal cancer precision medicine

Oncotarget. 2017 Apr 4;8(14):22305-22306. doi: 10.18632/oncotarget.15724.

Authors

Tsuyoshi Hamada¹, Jonathan A Nowak², Shuji Ogino^{1

2

3}

Affiliations

¹ Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
² Division of MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
³ Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

No abstract available

Keywords: clinical outcome; colorectal neoplasms; molecular pathological epidemiology; non-steroidal anti-inflammatory drugs; tumor microenvironment.

Publication types

News
Comment

MeSH terms

Class I Phosphatidylinositol 3-Kinases
Colorectal Neoplasms*
Humans
Liver Neoplasms*
Mutation
Phosphatidylinositol 3-Kinases / genetics
Precision Medicine

Substances

Phosphatidylinositol 3-Kinases
Class I Phosphatidylinositol 3-Kinases
PIK3CA protein, human